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ABSTRACT
Chemotherapy is one of the pillars of anti-cancer therapy. Although 
chemotherapeutics cause regression of the primary tumor, many chemotherapeutics 
are often shown to induce or accelerate metastasis formation. Moreover, metastatic 
tumors are largely resistant against chemotherapy. As more than 90% of cancer 
patients die due to metastases and not due to primary tumor formation, novel drugs 
are needed to overcome these shortcomings. In this study, we identified the anticancer 
phytochemical Rocaglamide (Roc-A) to be an inhibitor of cancer cell migration, a 
crucial event in metastasis formation. We show that Roc-A inhibits cellular migration 
and invasion independently of its anti-proliferative and cytotoxic effects in different 
types of human cancer cells. Mechanistically, Roc-A treatment induces F-actin-
based morphological changes in membrane protrusions. Further investigation of the 
molecular mechanisms revealed that Roc-A inhibits the activities of the small GTPases 
RhoA, Rac1 and Cdc42, the master regulators of cellular migration. Taken together, 
our results provide evidence that Roc-A may be a lead candidate for a new class of 
anticancer drugs that inhibit metastasis formation.
INTRODUCTION
Many chemotherapeutics currently used in anti-
cancer treatment mainly act by cytotoxicity. Although, 
chemotherapy frequently leads to shrinkage in primary 
tumor volume, several studies have shown that it may 
also induce or accelerate metastasis formation [1, 2]. One 
strategy to overcome this shortcoming is to develop small 
molecule drugs with antimetastatic activity in addition to 
the cytotoxicity towards cancer cells.
Cancer cell migration is a crucial process in 
metastasis formation. The first step in cellular migration 
is polarization of the cell. A leading and trailing edge form 
in response to an external gradient of signal molecules. In 
a second step the cell body at the leading edge protrudes 
and subsequently attaches to the underlying substratum. 
Eventually, the trailing edge detaches from the substratum 
and is pulled forward. The migration of the cell and the 
development of cellular protrusions are largely driven 
by the reorganization of the actin cytoskeleton [3]. 
Whereas actin polymerizes at the leading edge of the 
cell into F-actin, bundled F-actin fibers at the rear of the 
cell depolymerize. The forming actin meshwork at the 
leading edge of the cell is the driving force for membrane 
protrusions, such as the flat and elongated lamellipodia, 
which play a crucial part in directed cellular migration 
[4]. Among the main regulators of actin reorganization 
are the Rho GTPases RhoA, Rac1 and Cdc42 [5, 6]. 
Rho GTPases shuttle between a GTP-bound active and 
a GDP-bound inactive form. Loss-of function of any of 
these molecules has been described to largely inhibit the 
migratory behavior of cells [7].
The phytochemical Rocaglamide-A (Roc-A) 
belongs to the chemical class of cyclopenta[b]-
tetrahydrobenzofurans, collectively referred to as 
flavaglines or rocaglamides [8, 9]. In vivo and in vitro 
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studies have shown that flavaglines/rocaglamides are new 
candidate drugs for the treatment of cancer [10-14]. So 
far, the anti-tumor activities of these compounds have 
been documented to be largely due to inhibition of the 
eukaryotic translation initiation resulting in blockage 
of protein translation [12, 15-17]. In addition, a screen 
involving over 300,000 chemical compounds showed 
that Roc-A is also a potent inhibitor of HSF1 activation 
which is involved in cancer glucose uptake [13]. However, 
whether flavaglines could affect cancer cell migration and 
metastasis formation has not been thoroughly studied. In 
this study, we show that Roc-A inhibits cellular migration 
independent of its anti-proliferative and cytotoxic 
effects. We show that Roc-A treatment leads to major 
morphological changes in the organization of F-actin-
based protrusions, such as lamellipodia. By applying 
Förster resonance energy transfer (FRET)-microscopy 
we revealed that Roc-A reduces the activity of Rho 
GTPases RhoA, Rac1 and Cdc42. Taken together, our 
study suggests that Roc-A may be a promising candidate 
compound for preventing metastasis.
RESULTS
Roc-A inhibits cellular migration independent of 
its cytotoxic and anti-proliferative effects
We and others have previously shown that 
Roc-A and its derivatives exert their anticancer effects 
by inducing apoptosis as well as proliferation arrest 
(for review see [8]). Along with the study of the anti-
proliferative effect of Roc-A [10], we have also observed 
marked changes in cellular morphology in the prostate 
cancer cell line PC-3. Under Roc-A treatment, PC-3 cells 
were less elongated and frequently increased in diameter. 
To further investigate the influence of Roc-A in cellular 
morphology, we cultured PC-3 cells in a gradient of 
FCS ranging from 0 to 10 % in the presence or absence 
(solvent DMSO) of Roc-A. To exclude the possibility that 
the observed changes in cellular morphology were due to 
inhibition of protein synthesis or induction of apoptosis 
we first examined which doses of Roc-A have no or little 
effect on translation and cell death. Using an in vitro 
protein synthesis assay, we determined that Roc-A at the 
concentrations below or equal to 30 nM has no substantial 
effect on translation inhibition in PC3 cells (Figure 1A). 
Significant inhibition of protein synthesis by Roc-A was 
observed at 100 nM and higher (Supplementary Figure 
S1A). Roc-A also has little effect on apoptosis induction at 
concentrations below 50 nM (Supplementary Figure S1B). 
Therefore, we carried out all assays with 15 or 30 nM of 
Roc-A in PC3 cells.
Consistent with our initial observations, PC3 cells 
were less elongated when treated with Roc-A (Figure 
1B). In addition, Roc-A treatment decreased cell polarity 
by more than two-fold as determined by the number of 
cells aligned along the FCS gradient (Figure 1B and 
1C). Cell polarity is a crucial and first step in directed 
cellular migration. Therefore, we hypothesized that 
Roc-A treatment would prevent cellular migration. To 
test this hypothesis we first performed a wound-assay. In 
this assay, confluent cell layers are separated by a gap. 
Due to the lack of adjacent cells, cells migrate towards 
each other and close the gap over time. We observed that 
Roc-A treatment resulted in prevention of gap closure in 
a dose-dependent manner at concentrations of 15 – 30 nM 
in PC3 cells (Figure 1D and 1E). As Roc-A can block 
cellular proliferation by activation of the Chk1/2 
signaling pathway [10], we treated PC-3 cells with the 
anti-proliferative drug Mitomycin C (MC) to exclude the 
possibility that delayed gap closure was due to inhibition 
of cellular proliferation. Although MC treatment (5 μg/ml 
for 1h) led to a stronger inhibition of proliferation than 
Roc-A treatment (Figure 1F) it did not inhibit gap closure 
(Figure 1D and 1E). Increased exposure to cells with 
MC for more than 1h caused a similar level of cell death 
as Roc-A (Supplementary Figure S1B and S1C). These 
experiments exclude that the Roc-A-mediated delay in 
gap closure was due to inhibition of cellular proliferation. 
In addition to its anti-proliferative effects, Roc-A is also 
known to be cytotoxic to various cancer cell lines and 
primary cancer cells by induction of apoptotic cell death. 
To rule out that the observed delay in gap closure was 
caused by Roc-A-induced cell death, cell viability was 
examined by AnxV and 7-AAD staining after treatment. 
The experiments showed that Roc-A decreased PC3 cell 
viability by only 5 % when used at 30 nM (Figure 1G). 
However, gap closure was inhibited by approximately 
60% at the same concentration (Figure 1E). In addition, 
we used the pan-caspase inhibitor zVAD-fmk to block 
any occurring apoptosis in the assay. In the presence of 
zVAD-fmk, Roc-A-induced apoptosis was completely 
blocked (Figure 1G). However, inhibition of apoptosis 
did not significantly affect the gap closure (Figure 1D and 
1E). Taken together, these experiments demonstrate that 
Roc-A can inhibit cell migration independent from its anti-
proliferative and cytotoxic effects.
To investigate whether Roc-A can inhibit cell 
migration in general, we tested one normal (non-tumor) 
fibroblast cell line NIH-3T3 and four additional human 
cancer cell lines: transformed human embryonic kidney 
cell line 293T, breast cancer cell line MDA-MB-231, 
human colon cancer cell line HCT116, and human 
cervical cancer cell line HeLa. Consistent with the 
above results, Roc-A blocked gap closures in all cell 
lines tested in a dose-dependent manner (Figure 2A 
and 2B; Supplementary Figure S2 and S3). High doses 
of Roc-A can induce significant apoptotic cell death 
(Supplementary Figure S4). However, the concentrations 
of Roc-A used in the wound assays caused only 3-10% 
cell death (Supplementary Figure S4). In 293T and MDA-
MB-231 cells, for instance, Roc-A inhibited gap closure 
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by approximately 70-80% (Figure 2A and 2B). While MC 
treatment had no effect on gap closure (Figure 2A and 
2B), it inhibited cellular proliferation stronger (in 293T 
cells) or equipotent (in MDA-MB-231 cells) to Roc-A 
(Figure 2A-2C) and caused higher cell death (10-20%) 
than Roc-A (Supplementary Figure S5). Cell viability of 
293T cells was not affected by Roc-A at concentrations 
of 15 - 30 nM (Figure 2D; Supplementary Figure S3). 
In MDA-MB-231 cells, Roc-A treatment resulted in a 
decrease in cell viability of less than 5%, which could be 
blocked completely by zVAD-fmk (Figure 2D). Inhibition 
of apoptosis only marginally affected Roc-A-mediated 
inhibition of MDA-MB-231 cell migration (Figure 2B). 
Thus, the anti-migratory effect of Roc-A on PC-3 cells 
could be reproduced in other cell types suggesting that this 
effect is cell type-independent.
Figure 1: Roc-A inhibits PC-3 cell migration independent of its cytotoxic and anti-proliferative effects. A. Effect of 
Roc-A on protein translation. PC3 cells were treated with different doses of Roc-A as indicated. The activities of protein synthesis were 
monitored by incorporation of 35S-methionine. B. Roc-A decreases cell polarity in PC-3 cells. PC-3 cells were exposed to a gradient of FCS 
(0-10%) in the presence of 15 nM Roc-A or solvent (DMSO) for 20 h. Examples of polarized (arrow) and unpolarized (arrowhead) cells 
are indicated. Scale bare = 50 μm. Representative images are shown. C. Quantification of B. At least 230 cells per treatment were analyzed. 
Results are an average of three independent experiments. Error bars (S.D.) are shown. D. Wound assay. A gap was created in confluent 
PC-3 cell monolayers and then cells were treated with different concentrations of Roc-A in the absence or presence of zVAD (25 μM for 20 
min prior to treatment) for 16 h or treated with 5 μg/ml Mitomycin C (MC) for 1h as described in Material and Methods and then further 
cultured for 16 h. The gaps before (0 h) and after (16 h) treatment are shown. E. Quantification of the gap closure. The effects of different 
drugs on cell migration were quantified as percentage of gap closure. Results are an average of three independent experiments. Error bars 
(S.D.) are shown. F. Analysis of the effects of different drugs on proliferation. PC-3 cells were stained with CFSE as described in Materials 
and Methods and then seeded and treated as in C. The percentage of proliferative cells was determined and normalized to DMSO treatment. 
Results are an average of three independent experiments. Error bars (S.D.) are shown. G. Analysis of the effects of different drugs on cell 
viability. The percentage of viable cells was determined as AnxV-/7aad- cells 20 h after drug treatment. Results are an average of three 
independent experiments. Error bars (S.D.) are shown.
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Roc-A inhibits cancer cell invasion and impairs 
directed cellular migration
In order to form metastasis cancer cells need to 
leave the primary tumor site via the blood stream or 
lymphatic system. To reach blood or lymphatic vessels, 
extracellular matrix (ECM) constituents have to be 
degraded in a process termed invasion [18]. Therefore, 
we asked whether Roc-A is able to block the invasive 
behavior of cancer cells. To investigate this question, we 
used a Boydon Chamber assay with matrigel as an ECM 
substituent. PC3 cells were seeded in FCS-free medium 
on top of matrigel-coated filters in the presence of 15 nM 
Roc-A or solvent (DMSO). A gradient of FCS and/or EGF 
was generated by adding 100 ng/ml of EGF and/or 5 % 
FCS (used as a chemoattractant) to the well below the 
filter. The experiment showed that treatment of PC-3 cells 
with Roc-A for 24 h blocked FCS-attracted invasion to 
more than 70% (Figure 3A). Addition of EGF to FCS led 
to a twofold increase in cellular invasion, which could also 
be blocked by Roc-A (Figure 3A). These results indicate 
that Roc-A can inhibit cellular invasion.
Both, the wound (Figure 1D, 2A and 2B) assay and 
the invasion (Figure 3A) assay, however, measure cellular 
migration only indirectly. To directly analyze the effect 
of Roc-A on cellular migration we performed a live cell 
imaging experiment. In this experiment PC-3 cells were 
exposed to a gradient of FCS ranging from 0 to 10% and 
migration of individual cells were tracked over a time 
period of 20 h. In average, cells migrated towards the side 
of the chamber where FCS concentration was highest. In 
the presence of Roc-A, cellular migration was strongly 
Figure 2: Roc-A inhibits migration of different types of cancer cells. A and B. Roc-A inhibits cell migration in 293T and 
MDA-MB-231 cells. 293T and MDA-MB-231 cells were subjected to treatment with different drugs and the percentage of gap closure was 
quantified as described in Figure 1C and 1D. Representative images are shown. C. Analysis of the effects of different drugs on proliferation 
in 293T and MDM-MB-231 cells. The percentage of proliferative cells was determined and normalized to DMSO treatment. Results are an 
average of three independent experiments. Error bars (S.D.) are shown. D. Analysis of the effects of different drugs on cell viability. The 
percentage of viable cells was determined as AnxV-/7aad- cells 20 h (293T) and 24 h (MDA-MB-231) after drug treatment. Results are an 
average of three independent experiments. Error bars (S.D.) are shown.
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inhibited (Figure 3B, upper panel). Notably, Roc-A 
impaired all parameters of cellular migration measured 
(Figure 3B, lower panel). The strongest impairment was 
seen for the center of mass and Euclidean distance (Figure 
3B, lower panel). The former is a measure for average 
migration of the entire cell population in direction of 
FCS gradient and the latter describes the direct distance 
between the end and starting point of migration of each 
cell. In conclusion, this experiment indicates that directed 
migration is inhibited by Roc-A.
Roc-A alters the morphology of F-actin-based 
protrusions by an indirect effect on actin 
polymerization
One of the most crucial steps in cellular migration 
is reorganization of the actin cytoskeleton. During 
migration the monomeric form of actin polymerizes 
at the leading edge into a branched network of F-actin, 
while F-actin at the trailing edge is being degraded [19]. 
Due to the importance of actin reorganization in cellular 
migration, we further investigated the influence of Roc-A 
on actin reorganization. To do so, we performed confocal 
microscopy on F-actin stained cells. PC-3, 293T or MDA-
MB-231 cells were treated for 24 h with Roc-A or solvent 
(DMSO) and cells were subsequently stained for F-actin 
(Alexa Fluor 488-Phalloidin) and nuclei (DAPI). The 
experiment showed that Roc-A induced marked changes 
in F-actin-rich protrusions (Figure 4A). In PC3 cells, while 
control (DMSO-treated) cells showed filopodia, Roc-A-
treated cells largely lacked filopodia and showed increased 
membrane ruffling (Figure 4A, left panel). In 293T and 
MDA-MB-231 cells, Roc-A treatment caused a decrease 
in lamellipodia formation and rounding of cells (Figure 
4A, middle and right panel). In summary, Roc-A treatment 
causes marked changes in cell morphology and F-actin-
rich protrusions and the characteristics of these changes 
are different among different types of cancer cells.
Figure 3: Roc-A inhibits cancer cell invasion and impairs directed cellular migration. A. Roc-A inhibits PC-3 cell invasion. 
PC-3 cells were seeded in FCS-free medium on matrigel-coated filters and treated with 15 nM Roc-A or solvent (DMSO). A gradient of FCS 
and/or EGF was applied by adding 100 ng/ml EGF and/or 5 % FCS to the well below the filter. The upper panel shows the representative 
image. The lower panel shows the number of invasive cells determined 24 h after treatment and normalized to DMSO-treated cells. 
Representative images of calcein-stained cells are shown. Results are an average of four independent experiments. Error bars (S.D.) are 
shown. Asterisks indicate statistical significance with * p < 0.05, **p < 0.01, calculated by unpaired Student’s t-test with Welch’s correction. 
B. Roc-A impairs directed cellular migration in PC-3 cells. PC-3 cells were exposed to a gradient of FCS (0-10%) and in parallel treated 
with 15 nM Roc-A or solvent (DMSO). The upper panel shows the movement of 30 cells per treatment tracked over a period of 24 h. Black 
dots show relative cell positions over 24 h and the green dot indicates the center of mass at the end of the observation period. The lower 
panel shows the parameters of cellular migration determined. Results are an average of three independent experiments. Error bars (S.D.) are 
shown. Asterisks indicate statistical significance with * p < 0.05, **p < 0.01, calculated by unpaired Student’s t-test with Welch’s correction.
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To analyze whether the morphological changes in 
F-actin-based protrusions were caused by a direct effect 
of Roc-A on actin polymerization or depolymerization, 
we performed a cell-free in vitro polymerization or 
depolymerization assay. In the actin polymerization assay, 
pyrene-conjugated monomeric actin is polymerized, 
leading to an increase in fluorescence. The actin 
polymerization-inducer Jasplakinolide was used as a 
positive control. While Jasplakinolide accelerated the 
rate of actin polymerization, Roc-A treatment did not 
differ from the control treatment (Figure 4B). To further 
analyze whether Roc-A could influence the stability of 
preformed F-actin filaments directly, we performed a cell-
free in vitro depolymerization assay. While the known 
F-actin stabilizing agent Phalloidin strongly delayed 
F-actin depolymerization, Roc-A did not alter the rate of 
depolymerizaton (Figure 4C). These results suggest that 
Roc-A has no direct effect on F-actin stability, neither on 
actin polymerization nor on actin depolymerization of 
F-actin filaments.
Roc-A inhibits the activity of the Rho GTPases 
RhoA, Rac1 and Cdc42
As Roc-A did not influence F-actin polymerization 
directly (Figure 4B and 4C), we asked whether Roc-A 
affects activities of the upstream regulators of actin 
remodeling. The Rho GTPases RhoA, Rac1 and Cdc42 
have been shown to be the main upstream regulators of 
actin remodeling [5, 6]. Therefore, we further investigated 
the role of Roc-A in regulation of the activities of Rho 
GTPases by transfection of 293T cells with Förster 
Figure 4: Roc-A alters the morphology of F-actin-based protrusions by an indirect effect on actin polymerization. A. 
Roc-A alters the morphology of F-actin-based protrusions. PC-3, MDA-MB-231 and 293T cells were treated with Roc-A (15 nM for PC3, 
60 nM for MDA-MB-231 and 30 nM for 293T) or solvent (DMSO) for 24h followed by staining of F-actin (green) and nuclei (blue). Three 
independent experiments were carried out per cell line. Representative images (Z-stacks) per cell line are shown. Scale bar = 20 μm (PC-3) 
or 10 μm (293T and MDA-MB-231). B. Roc-A does not directly affect actin polymerization. The influence of Roc-A on polymerization of 
pyrene-conjugated actin monomers was monitored by measuring the increase in fluorescence that occurs upon polymerization of pyrene-
conjugated actin. Roc-A, solvent control or the known actin polymerization promoting agent Jasplakinolide were added to pyrene-conjugated 
actin monomers and 20 min later actin polymerization was initiated. Results are representative of three independent experiments. C. Roc-A 
does not directly affect actin depolymerization. The influence of Roc-A on depolymerization of pyrene-conjugated actin monomers was 
monitored by measuring the decrease in fluorescence that occurs upon depolymeization of pyrene-conjugated actin. Roc-A, solvent control 
or the known F-actin stabilizer phalloidin were added to polymerized pyrene-conjugated actin for 20 min, after which depolymerization of 
actin was initiated. Results are representative of three independent experiments.
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Resonance Energy Transfer (FRET)-based Rho GTPase 
sensors for RhoA, Rac1 or Cdc42 [20-22]. The transfected 
cells were treated with Roc-A or solvent DMSO as 
control. A decrease in Rho GTPase activity would result 
in reduction in FRET efficiency which can be monitored 
by fluorescence microscopy. We also cotransfected FRET-
Rho GTPase sensors with excess RhoGDI, a physiologic 
regulator of Rho GTPase activity that is known to bind 
and stabilize Rho GTPases in their inactive state [20-23]. 
We thus created a situation with maximal physiological 
inhibition of the Rho GTPase activity and comparability 
between the three Rho GTPases used. As shown in 
Figure 5A and 5B, Roc-A inhibited the activity of RhoA, 
Rac1 and Cdc42 by approximately 15 to 22 %, with 
the strongest effect towards Cdc42 and RhoA. Similar 
results (approximately 15 to 31% inhibition) were also 
observed when the experiments were carried out in HeLa 
cells (Figure 5C). Thus, Roc-A can inhibit the activities 
of RhoA, Rac1 and Cdc42. To investigate whether the 
reduced Rho GTPase activity is due to reduction in protein 
expression, we examined the protein levels in PC3, MDA-
MB-231 and 293T cells after Roc-A treatment for 24 h by 
immunoblot. The analysis showed that Roc-A treatment 
did not affect the expression levels of the Rho GTPases 
(Supplementary Figure S6). This is in line with the 
fact that the concentrations of Roc-A used in this study 
had little effects on protein translation (Figure 1A and 
Supplementary Figure S1A).
Since the activity of Rho GTPases is positively 
regulated by guanine nucleotide exchange factors (GEFs) 
and negatively regulated by GTPase activating proteins 
(GAPs) [24, 25], we asked whether Roc-A could directly 
interfere with GEF-mediated activation or GAP-mediated 
inactivation of Rho proteins. To answer this question, we 
performed an in vitro GEF/GAP activity assay based on 
fluorescent mant-GDP/tamra-GTP bound Rho GTPases 
[26]. Roc-A was shown to neither affect the activation of 
Rho GTPases madiated by specific GEFs (LARG, Vav2 
and ITSN; Figure 6A) nor the inactivation of Rho GTPases 
mediated by p50GAP (Figure 6B). These results clearly 
ruled out the possibility that Roc-A directly interferes with 
the activity of GEFs or GAPs in general.
Besides GAPs and GEFs, Rho GTPase activity 
can also be regulated by Rho-specific guanine nucleotide 
dissociation inhibitor (GDI). GDI binding to Rho 
GTPases blocks their activity and prevents them from 
translocating to the plasma membrane [20-22, 27]. To 
address this possibility, we performed a GDI knockdown 
Figure 5: Roc-A inhibits the activity of the Rho GTPases RhoA, Rac1 and Cdc42. A. Roc-A inhibits the activity of the Rho 
GTPases RhoA, Rac1 and Cdc42. RhoA, Rac1 or Cdc42 FRET sensors were overexpressed in 293T cells either with a control plasmid 
(Control, 30 nM Roc-A) or together with GDI. Cells were treated with 30 nM Roc-A or vehicle (DMSO for Control and GDI) for 24h. 
Representative fluorescence micrographs show mVenus channel of 293T cells expressing the indicated FRET sensors. Scale bars: 100 μm. 
Pseudocolored FRET efficiency images of the same field of view were calculated as a ratio of FRET acceptor over FRET donor emission 
intensity reflecting the GTPase activity levels. The histograms show the pixel distribution of the FRET efficiency within the FRET emission 
ratio images. B. Quantification of A. FRET efficiency was normalized to GDI and DMSO values and % inhibition FRET efficiency was 
calculated. Results are an average of six independent experiments. Error bars (S.E.M.) are shown. C. Roc-A inhibits the activity of the Rho 
GTPases RhoA, Rac1 and Cdc42 in HeLa cells. RhoA, Rac1 or Cdc42 FRET sensors were overexpressed in HeLa cells either with a control 
plasmid (Control, 30 nM Roc-A) or together with GDI. Cells were treated with 30 nM Roc-A or vehicle (DMSO for Control and GDI) for 
24h. FRET efficiency was normalized to GDI and DMSO values and % inhibition FRET efficiency was calculated. Results are an average 
of three independent experiments. Error bars (S.E.M.) are shown.
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experiment. Cells were stably transfected with shRNAs 
directed against GDI or control. The sequence of shRNA 
was designed to target an untranslated region of GDI to 
only interfere with the endogenous GDI expression. The 
experiment showed that knockdown of GDI did not affect 
the inhibitory effect of Roc-A on the activity of RhoA 
(Supplementary Figure S7). Thus, this experiment also 
ruled out that Roc-A might inhibit Rho GTPase activity 
through stabilizing the binding of GDI to Rho GTPases.
Whereas RhoA is mainly found in the cytoplasm, 
Rac1 has been described to be additionally localized at the 
plasma membrane and Cdc42 only minimally localizes to 
the plasma membrane [28]. Certain molecules have been 
described to influence the localization of Rho GTPases 
[29, 30]. To analyze whether Roc-A may influence the 
intracellular localization of Cdc42, Rac1 or RhoA, we 
coexpressed the respective RhoGTPaes together with 
the plasma membrane marker tH and examined their 
membrane localization by confocal microscopy. As 
described in the literature, RhoA was mainly expressed 
in the cytoplasm, whereas Rac-1 was also localized at 
the plasma membrane overlapping with tH expression 
(Supplementary Figure S8). Cdc42 was only partially 
found at the plasma membrane with clearly dominant 
cytoplasmic localization. We could not observe any 
changes in the intracellular localization of all three Rho 
GTPases upon Roc-A treatment, ruling out that Roc-A 
interferes with the intracellular localization of Rho 
GTPases.
In an attempt to find putative upstream pathways 
with which Roc-A might interfere to attenuate Rho 
GTPase activity, we looked for known intracellular 
interaction partners of Roc-A. Recently, we have identified 
prohibitin (PHB) as the direct target of rocaglamides [16]. 
Binding of rocaglamides to PHB prevents interaction 
between PHB and CRaf and, consequently, inhibits CRaf 
activation and CRaf-MEK-ERK signalling. This action 
leads to inhibition of protein synthesis [16]. Therefore, we 
examined the ERK activity at 15 nM Roc-A treatment. 
Consistent with the translation data (Figure 1A), Roc-A 
had no influence on ERK activity at the concentration of 
15 nM (Supplementary Figure S9A). To further investigate 
Figure 6: Roc-A does not directly interfere with the activity of GEFs or GAPs. A. No significant effect of Roc-A on the 
GEF-accelerated nucleotide exchange of Rho proteins. Dissociation of fluorescent mant-GDP from Rho proteins (RhoA, Rac1 and Cdc42, 
respectively), accelerated by the RhoGEFs (LARG, Vav2 and ITSN, respectively), was monitored in the absence (green) and in the presence 
(red) of Roc-A (10 μM). The reactions without RhoGEFs are shown in black. In the right panel, observed rate constants (kobs) of the 
respective measurements are illustrated. B. No significant effect of Roc-A on the GAP-accelerated GTP hydrolysis of Rho proteins. GTP 
hydrolysis of fluorescent tamra-GTP by Rac1 and Cdc42, respectively, and cy3-GTP by RhoA, stimulated by p50GAP, was monitored in 
the absence (green) and in the presence (red) of Roc-A (10 μM). The reactions in absence of GAP are shown in black. In the right panel, 
observed rate constants (kobs) of the respective measurements are illustrated. All data shown in A and B are an average of four to five 
different experiments. C. Schematic representation of the mechanism by which Roc-A inhibits cellular migration. We hypothesize that 
Roc-A blocks a signal upstream of Rho-GTPases leading to down-regulation of Rho-GTPase activities and, consequently, inhibition of 
cellular migration.
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whether the CRaf-MEK-ERK signalling pathway is 
necessary for Roc-A-mediated inhibition of cell migration, 
we carried out a siRNA approach to knockdown PHB 
expression. The experiment showed that knockdown of 
PHB in PC3 cells had no influence on the effect of Roc-A 
on inhibition of cell migration (Supplementary Figure S9B 
and S9C).
In summary, Roc-A inhibits the activation of Rho 
GTPases Cdc42, Rac1 and RhoA by an indirect effect and 
independent from the previously described target protein 
prohibitin.
DISCUSSION
Metastasis formation is the major cause of death in 
cancer patients [18]. So far, most cancer treatments are 
not efficient in fighting metastases because tumors often 
develop chemo-resistance during therapy [18]. Several 
studies even show that chemotherapy may enhance 
metastasis formation [1, 2]. For instance, cisplatin 
or paclitaxel treatment has been reported to enhance 
metastasis formation in an in vivo lung metastasis 
model [2]. This side effect highlights a demand for new 
anticancer drugs that can efficiently kill tumor cells and 
also inhibit metastasis formation at the same time. In this 
study, we show that Roc-A may be a promising candidate 
for such a drug.
To firmly confirm the role of Roc-A in inhibition 
of cellular migration of cancer cells, we performed 
three different assays: wound-assay (Figures 1 and 2), 
invasion assay (Figure 3A) and live cell imaging of 
cellular migration at very low concentrations (15 to 30 
nM) of Roc-A which have no or only minor influence 
on viability of tumor cells (Figure 3B). All three assays 
showed a 50 – 80% inhibition of tumor cell migration/
invasion after treatment with Roc-A. Roc-A is known to 
have several other anticancer properties such as inhibition 
of cell proliferation and induction of apoptosis [10, 15, 
16, 31]. Thus, we carried out the assays in the presence of 
the anti-proliferative drug Mitomycin-C (MC) or the pan-
caspase inhibitor zVAD to exclude the possibility that the 
observed effect of Roc-A on cellular migration was due to 
its anti-proliferative or cytotoxic activities. We show that 
Roc-A inhibits tumor cell migration independently of its 
anti-proliferative or cytotoxic effects by three evidences: 
First, the anti-proliferative drug MC did not influence 
cellular migration, although it inhibited proliferation to a 
similar or even a higher extent than Roc-A (Figures 1D 
and 2E); second, the concentrations of Roc-A used in cell 
migration assays caused only 5% or less apoptotic cell 
death (Figures 1G and 2D); and third, the pan-caspase 
inhibitor zVAD could not prevent Roc-A-mediated 
inhibition of gap closure (Figure 1D, 1E and 2A, 2B, 
2D). We found that Roc-A can also inhibit migration of 
non-tumor cells tested on the normal fibroblast NIH-3T3 
cells. However, it is not uncommon that anti-metastatic 
drugs can also block the migration of non-malignant cells. 
For instance, anti-metastatic Axl-kinase inhibitors are 
already in clinical trials [32], despite the fact that Axl-
deficient primary fibroblasts show reduced migration [33]. 
In comparison to the more severe side effects observed 
for most chemotherapeutics (anemia, neutropenia etc.), 
wound-healing impairment would not be graded as severe. 
In this regard, we and others have shown that Roc-A is 
less toxic to many primary non-malignant cells than 
most chemotherapeutics [8]. Additionally, Roc-A and its 
derivatives have been tested in several in vivo models. 
Thus far, no adverse toxicities caused by impaired wound 
healing could be observed. Nevertheless, future in vivo 
studies should particularly monitor for wound healing-
related side effects.
Recently, an in vivo study with a mouse pancreatic 
cancer model showed that Roc-A treatment resulted in 
a significant increase in the lifespan of tumor-bearing 
mice [34]. In consistence with our study, the study also 
observed a reduction in tumor metastasis in the lung [34]. 
However, in that study the concentrations of Roc-A used 
are quite high and were shown to kill the tumor cells 
by approximately 50% already. Therefore, it cannot be 
excluded that the observed effect of Roc-A on metastasis 
may be largely due to death of cells or inhibition of cell 
proliferation. In our study, we convincingly demonstrate 
that Roc-A can inhibit cancer cell migration and invasion 
independently of its cytotoxic and anti-proliferative 
activities. Furthermore, our data also show that the 
inhibitory effect of Roc-A on tumor cell migration is not 
limited to a specific cancer-type. We have investigated the 
effect of Roc-A on three different types of cancers: PC-3 
(prostate cancer), MDA-MB-231 (breast cancer) and 293T 
(transformed embryonic kidney). All three cancer types 
showed a similar response to Roc-A treatment. Thus, 
Roc-A may be applicable to a wide variety of tumor cells.
In this study, we also further investigated the 
molecular mechanism by which Roc-A inhibits cellular 
migration. We found that Roc-A inhibited the activity 
of all three Rho GTPases (Rac1, RhoA and Cdc42) by 
approximately 15 to 22% (Figure 5). Rac1, RhoA and 
Cdc42 are the major regulators of actin remodeling, with 
their interplay determining the orientation, direction and 
speed of cellular migration [6, 35]. It has been shown that 
an increase in only 30% activity of RhoA could cause 
an increase in cellular migration by approximately 80% 
[36]. Therefore, we assume that reduction of about 20% 
of the activities of all three Rho GTPases may lead to a 
significant reduction of cellular migration. However, 
we cannot exclude that Roc-A may alter other signaling 
pathways next to Rho GTPase inhibition that contribute 
to a reduction in cellular migration. In addition, numerous 
loss-of-function studies have shown that loss of either 
of the three Rho GTPases causes a dramatic decrease in 
cellular migration in many cell types [35]. Coinciding with 
the inhibition of Rho GTPases by Roc-A, we found that 
Oncotarget51917www.impactjournals.com/oncotarget
Roc-A treatment induced marked changes in morphology 
of F-actin-rich protrusions (Figure 4A). Roc-A treatment 
inhibited formation of filopodia (Figure 4, left panel) and 
lamellipodia (Figure 4, middle and right panel). Inhibition 
of Rac1 in MDA-MB-231 cells was shown to result in 
failure of lamellipodia formation and, subsequently, 
in cellular migration [37]. Hence, Roc-A-mediated 
inhibition of Rho GTPases may be one of the molecular 
mechanisms by which Roc-A causes changes in F-actin-
based protrusions (Figure 4) and inhibition of cellular 
migration (Figures 1-3; Supplementary Figure S2 and 
S3). Furthermore, reorganization of actin was shown to be 
necessary for cellular migration [38]. For instance, drugs, 
such as Cytochalasin D or Jasplinakolide that interfere with 
actin polymerization directly, strongly inhibit cancer cell 
migration [39, 40]. Thus, alteration of F-actin morphology 
by Roc-A is in line with its anti-migratory effect.
In an attempt to unravel the underlying mechanism 
behind the inhibitory effect of Roc-A on Rho GTPases, we 
could show that Roc-A did neither influence the expression 
level nor intracellular localization of Rho GTPases, nor 
did it interfere with direct binding of GEFs, GAPs or GDIs 
to Rho GTPases. Consequently, the effect of Roc-A on 
Rho GTPase activity most likely is being located more 
upstream in the signaling pathway (Figure 6C). As we 
could exclude that the inhibitory effect of Roc-A on Rho 
GTPase activity is mediated by prohibitin or protein 
translation, another yet undiscovered target of Roc-A must 
show responsible for the observed inhibitory effect.
So far, the main mechanisms by which Roc-A inhibits 
cancer cell proliferation have been shown to be due to 
inhibition of protein synthesis initiation [8] and induction 
of Cdc25A degradation by activation of the ATM/ATR 
check point pathway [10]. As shown in our study (Figures 
1F and 2C), Roc-A substantially inhibited cell proliferation 
although the doses used had no or little effect on translation 
inhibition. Rho GTPases have been described to be involved 
in regulation of cell cycle progression. Several studies show 
that inhibition of Rho GTPase activity causes inhibition of 
cell proliferation [5, 41]. Thus, inhibition of Rho GTPase 
activity by Roc-A may explain the anti-proliferative effect 
observed at low concentrations of Roc-A.
Taken together, we show that Roc-A does not only 
exert cytotoxic and cytostatic effects on cancer cells, but 
also inhibits tumor cell migration most likely via inhibition 
of activities of Rho GTPases (Figure 6C). Our study 
strongly suggests that Roc-A may be a lead compound for 
a new class of chemotherapeutic drugs that kill tumor cells 
and prevent metastasis at the same time.
EXPERIMENTAL PROCEDURES
Cell culture and reagents
The non-tumor fibroblast cell line NIH-3T3, 
the human cell lines PC-3 (prostate cancer), MDA-
MB-231 (breast cancer), the human colon cancer cell 
line HCT116, the human cervical cancer cell line HeLa, 
and 293T (transformed embryonic kidney) were cultured 
at 37°C with 5% CO2 in RPMI-1640 medium (Sigma-
Aldrich, Munich, Germany) supplemented with 10 % 
FCS (PC-3 and MDA-MB-231) or in DMEM medium 
(Sigma-Aldrich) supplemented with 10 % FCS (293T) 
until otherwise stated in the text. Roc-A (>98 % pure) 
(Enzo Life Sciences, Lörrach, Germany), Mitomycin-C 
(Gerbu Biotechnik, Heidelberg, Germany), zVAD-fmk 
(Bachem, Bubendorf, Switzerland), recombinant human 
EGF (BioVision, Milpitas, USA), Jasplakinolide (VWR 
international, Darmstadt, Germany) and Phalloidin 
(Biotrend, Köln, Germany) were used as indicated in the 
respective figure legends.
Wound assay
Cells were seeded in wound assay cell culture 
inserts (Ibidi, Munich, Germany) and cultivated until 100 
% confluence was reached. Subsequently, inserts were 
removed and cell layers were washed with phosphate 
buffered saline (PBS), followed by addition of fresh 
medium containing either Mitomycin-C, solvent (DMSO) 
as control or Roc-A. After 1 h Mitomycin-C was washed 
out and fresh medium was added. ZVAD-fmk was added to 
indicated samples 20 min prior to adding solvent (DMSO) 
or Roc-A. Pictures of the gap between the two cell layers 
were taken directly after addition of drugs and at the end 
of the indicated incubation time. The change in cell-free 
surface over time was quantified by use of TScratch [42] 
and normalized to DMSO-treated control samples.
Determination of cell viability
Cells that were previously analyzed in wound 
assays, were detached by trypsinization and washed once 
with Annexin-V binding buffer (0.01 M Hepes, 2.5 mM 
CaCl2, 0.14 M NaCl). Subsequently, cells were stained 
with 7-amino-actinomycin D (7-aad; Sigma-Aldrich) and 
Annexin-V–FITC antibody (Immunotools, Friesoythe, 
Germany) at 4°C for 30 min, followed by a wash step and 
quantification of Annexin-V/7-aad double-negative cells 
by flow cytometry.
Determination of cell proliferation
Cells were labeled with carboxyfluorescein 
succinimidyl ester (CFSE; Molecular Probes/Thermo 
Fisher Scientific, Waltham, USA) by incubation of 2 x 
106 cells with CFSE (2.5 μM) for 10 min at 37°C in the 
dark. Incorporation was stopped by addition of ice-cold 
FCS (10% in PBS). Subsequently, cells were washed 
three times and were employed in wound assays. 24 h 
after drug treatment, the amount of incorporated CFSE 
was quantified by flow cytometry. Proliferation data was 
normalized to DMSO-treated samples.
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Invasion assay
Invasion assays were carried out according to 
the manufacturer´s instructions. Briefly, 8.5 x 104 cells 
were plated on top of each rehydrated culture insert 
(BD BioCoat™ Matrigel™ Invasion Chamber; BD 
Biosciences, Heidelberg, Germany) in FCS-free medium. 
Following an incubation time of 24 h, remaining cells in 
the upper compartment were removed and cells that had 
migrated through Matrigel™ were stained with Calcein 
(4 μM; Sigma-Aldrich), followed by quantification as 
previously described [43].
Chemotaxis assay
For 2D chemotaxis assays “μ-Slide Chemotaxis”-
chambers (Ibidi, Munich, Germany) were used. 
Chemotaxis assays were carried out according to the 
manufacturer´s instructions. Cells that divided or died 
during the observation period were excluded from analysis. 
Images were taken every 5 min for an observation period 
of 20 h. ImageJ [44] was used for tracking of cells and 
Chemotaxis and Migration Tool (Ibidi, Munich, Germany) 
was used for evaluating tracked cell data.
Confocal microscopy
0.4 x 104 – 0.4 x 105 cells were seeded in each well 
of a 8-well chamber glass slide (VWR International, 
Darmstadt, Germany), followed by starvation of cells for 
24h in FCS-free medium. In parallel, cells were treated 
as indicated in the figure legends after which 10 % FCS 
(in medium) was added for 30 min to stimulate growth 
factor signaling. Subsequently, cells were washed with 
PBS twice, fixed with formaldehyde (3%, 15 min), 
washed three times again with PBS and permeabilized 
with Triton-X 100 (0.2 %, 10 min). Three PBS wash 
steps were followed by staining actin with acti-stain 488 
phalloidin (Tebu, Offenbach, Germany) for 30 min at 
room temperature. DAPI mounting medium (Dianova, 
Hamburg, Germany) was used to stain nuclei.
Actin (De)polymerization assay
Actin (De)Polymerization Assays were carried 
out according to manufacturer´s instructions using Actin 
Polymerization Biochem Kit (Cytoskeleton Inc, Denver, 
USA). Fluorescence was measured for a total time of 120 
min with 60 sec intervals. Baseline fluorescence values 
were established by measurement of unpolymerized 
pyrene actin or polymerized pyrene actin, respectively, for 
5 min, after which drugs or solvent were added. For actin 
polymerization experiments, actin polymerization was 
initiated by addition of 10 x Actin Polymerization Buffer 
(500 mM KCl, 20 mM MgCl2, 10 mM ATP) 20 min after 
drugs were added.
Rho GTPase activity measurement – FRET 
imaging
To study the effect of Roc-A on Rho GTPase 
activity, 293T cells were transiently transfected with 
RhoA, Rac1 and Cdc42 FRET sensors [20-22, 45] for 
40 h. Each Rho GTPase used in these measurements is 
labeled with a donor and an acceptor fluorophore. Upon 
activation of the Rho GTPase, the donor and acceptor 
fluorophores get into close proximity causing an increase 
in FRET efficiency. Imaging was performed on an inverted 
microscope (IX81, Olympus) equipped with a xenon 
arc burner epifluorescence illumination system (MT20, 
Olympus), a fluorescence emission filter wheel (Olympus) 
and an EM-CCD camera (ImagEM, Hamamatsu). Images 
were taken with a 10x/NA 0.4 Super Apochromat air 
objective (Olympus) enabling the simultaneous analysis 
of multiple cells. FRET images were taken with the 
following settings (excitation, dichroic mirror, emission): 
FRET-donor 430/25, zt442RDC, 483/32; FRET-acceptor 
430/25, zt442RDC, 542/27. Images were analyzed using 
Image J software. Images were background corrected and 
regions of interest were defined by FRET-sensor Venus 
intensity. Average intensities of FRET-acceptor channel 
were divided by FRET-donor channel to calculate FRET 
efficiency. To study the effect of Roc-A on Rho GTPase 
activity in HeLa cells, 1.25 x 104 cells were seeded into 
each well of a 96 well plate (μ-plate, ibidi). The next day, 
cells were transiently transfected with FRET sensors for 
RhoA, Rac1 and Cdc42, together with a control plasmid 
or GDI for 24h. Cells were then treated with 30 nM 
Roc-A or vehicle (DMSO for Control and GDI) for 24h. 
Images were taken using a 20x/NA 0.75 UV Apochromat 
objective (Olympus). FRET ratio was normalized to the 
DMSO control.
Translation assay
The rate of protein synthesis was determined by 
measuring the amount of incorporated 35S-methionine. 
Briefly, cells were incubated for 3 h in methionine-free 
medium, followed by addition of 7 μCi of 35S-methionine-
labeling mix (PerkinElmer, Waltham, MA, USA) per well. 
An incubation of indicated times was followed by washing 
with PBS and lysis in ice-cold lysis buffer for 15 min on 
ice. After clearing of cell lysates 50 μl of each lysate was 
incubated in 1 ml of Liquid Scintillation Cocktail solution 
(Beckman coulter, Brea, CA, USA) and radioactivity was 
determined by Liquid Scintillation counting.
siRNA knockdown experiment
PC-3 cells were transiently transfected with siRNA 
directed against PHB (FlexiTube siRNA Hs_PHB_6 
[Qiagen, Hilden, Germany]) by use of Lipofectamine 2000 
according to the manufacturer´s instructions. Transfections 
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were performed in Opti-MEM-GlutaMAX Medium 
(Thermo Fisher, Waltham, MA, USA).
GEF and GAP activity measurements
Human RhoA (aa 1-181), Rac1 (aa 1-184), Cdc42 
(aa 1-178), the catalytic DH-PH tandem domain of 
Vav2 (aa 168–543), ITSN (aa 1229–1580), LARG (aa 
766–1138) and GAP domain of p50 (aa 198-439) were 
produced as glutathione S-transferase (GST) fusion 
proteins in Escherichia coli as described previously [26]. 
Rho protein preparation, including nucleotide-free and 
fluorescent methylanthraniloyl (mant) GDP/GTP-bound 
Rho proteins, were prepared as described before [46]. 
For kinetic measurement, Fluorescence measurements 
were performed at 25°C in a buffer, containing 30 mM 
Tris/HCl, pH 7.5, 10 mM K2HPO4/KH2PO4, pH 7.5, 
5 mM MgCl2, and 3 mM dithiothreitol. Changes in 
fluorescent intensity were monitored in real-time using a 
stopped-flow instrument (HiTech Scientific SF-61) with 
a mercury xenon light source and TgK Scientific Kinetic 
Studio software. For measurement of GEF activity, the 
dissociation of mant-GDP from Rho proteins (0.2 μM) in 
the absence and presence of the DH-PH domain (2 μM) 
of the respective GEFs and excess amounts of GDP (20 
μM) was monitored (in absence and presence of Roc-A) 
[47]. An excitation wavelength of 366 nm was used and 
emission was detected using a cutoff filter of 408 nm. For 
measurement of GAP activity, fluorescent GTP-bound 
Rho proteins (pre-mixing 0.3 μM nucleotide-free Rho 
and 0.2 μM tamra-/cy3-GTP) and the catalytic domain 
of p50GAP (2 μM) were rapidly mixed by stopped-flow 
spectrophotometer (in absence and presence of Roc-A) 
[48]. Excitation wavelengths of 546 nm and 550 nm were 
used for tamra and cy3 fluorophores, respectively, and a 
570 nm (tamra and cy3) cut-off-filter (Schott glass) was 
used to collect emitted light. The observed rate constants 
were calculated by fitting the data as single exponential 
decay using the GraFit program (Erithacus software).
Localization of Rho GTPases after RocA 
treatment
1.25 x 104 cells (HeLa) were seeded on each well 
of an 8 well slide (μ-slide, ibidi). The next day, cells were 
transiently transfected with mCitrine-RhoA, mCitrine-
Rac1 or mCitrine-Cdc42 each together with mCerulean-
tH which comprises only the C-terminal 10 amino acids 
of HRas and, thus, served as a plasma membrane marker 
[49, 50]. Cells were treated with 30 nM Roc-A or vehicle 
(DMSO for Control and GDI) for 24h. Images were taken 
using a SP8 inverted confocal microscope equipped 
with a HC PL APO 63x/NA 1.3 glycerol objective. 
Representative images (Z-slices) are shown.
GDI-knockdown by shRNA lentiviral vector
To generate cell lines with stable RNAi knockdown 
of GDI, lentiviral shRNA-mediated stable gene 
silencing cells was done in 293T as described [51]. 
CGTCTAACCATGATGCCTTAA was used as targeting 
sequence in the shRNA and the 1.9 kb stuffer sequence 
as control. 5.5 x 104 cells of each cell line were seeded on 
each well of a 96 well plate (μ-plate, ibidi). The next day, 
cells were transiently transfected with FRET sensors for 
RhoA, Rac1 and Cdc42, together with a control plasmid or 
GDI for 24h. Cells were then treated with 30 nM Roc-A or 
vehicle (DMSO for Control and GDI) for 24h. FRET ratio 
was normalized to DMSO control. Results are an average 
of four experiments.
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